Article Text

PDF
AB0713 Botulinum Toxin-A for the Treatment of Severe Raynaud's Phenomenon
  1. L. Ruiz Gutiérrez1,
  2. A. Pérez Gόmez1,
  3. N. Valdeolivas Casillas2,
  4. A. Movasat1,
  5. E. Cuende Quintana1,
  6. A. Sánchez Atrio1,
  7. A. Turriόn Nieves1,
  8. C. Bohόrquez Heras1,
  9. F. Albarrán Hernández1,
  10. H. Moruno Cruz1,
  11. M.L. Romero Bogado1,
  12. S. Medina Montalvo2,
  13. M. Άlvarez de Mon1
  1. 1Immune System Diseases/Rheumatology
  2. 2Dermatology, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain

Abstract

Background Raynaud's phenomenon (RP) is characterized by transient episodes of vasoconstriction of the arteries and arterioles of the extremities in response to cold or emotional stimuli. Depending on the severity of the vascular insult, it can cause superficial ulceration or deep-tissue necrosis. Pharmacological treatments aim to enhance blood flow but their efficacy is not uniform.

Objectives To evaluate the efficacy of botulinum toxin-A in the treatment of severe RP.

Methods We present a series of 7 patients with RP with bad response to conventional pharmacological therapy that have been treated with local botulinum neurotoxin-A. Exclusion criteria included botulinum toxin allergy, active infection at the site of injection, previous digital sympathectomy and pregnancy.

4 to 8 units of botulinum toxin-A were administered per point of injection depending on the degree of severity. Points of injection were located on the lateral and medial aspect of the base of the fingers, except the thumb. Prior to infiltration, obstructive pathology was ruled out by Doppler ultrasound; also, a nailfold capillaroscopy test was performed before and after the infiltration. Variables such as the number of episodes per day, pain during the episodes, recuperation time, finger color and presence of digital ulceration or necrosis have been studied baseline, 30 minutes, one week and one month after the infiltration.

Follow up of 6 patients was performed with a 9 weeks median, being 18 weeks the maximum time registered. Patient 1 died due to a peritonitis 3 days after the study started.

Results 30 minutes after infiltration, three patients felt no improvement, two assessed slight improvement and two very important improvement. At the patients' one-week and thirty-days follow-up visits two patients did not perceive any change and four experienced great amelioration. Patients that did not register any change where those with fewer subjective clinical complaints and normal Doppler ultrasound and capillaroscopy tests.

The variable with the most remarkable response was pain, with important pain decrease in all of the cases. Three patients presented digit ulcers at baseline visit; ulceration healing was noted in all of them, two of them one week after the injection and the other one, one month after.

Three patients reported mild “weakness” after being injected and one reported slight thenar-eminence pain that lasted a few days. None of the patients suffered any systemic complications related to the toxin.

Conclusions Botulinum toxin-A is a safe and effective therapeutic option for patients with severe RP that have failed to conventional treatment.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.